Pulmonary vascular disease & thromboembolism
Predictors of outcomes in mild pulmonary hypertension according to 2022 ESC/ERS Guidelines: the EVIDENCE-PAH UK study
Authors' conclusion
The newly included patients have an increased mortality independent of significant lung or heart disease.
Study context
- Population
- Patients referred to UK pulmonary hypertension (PH) centres between 2009 and 2017
- Participants
- 2,929 patients
- Exposure
- Mildly elevated mean pulmonary artery pressure (mPAP) or pulmonary vascular resistance (PVR) vs normal haemodynamics
- mPAP <21 mmHgn = 968reference
- mPAP 21-24 mmHgn = 689
- mPAP ≥25 mmHgn = 1,272
- Outcome
- Survival
Methodological detailsnationwide
- Nationwide
Main finding
As reported in the abstract
All-cause mortality (survival), mildly elevated vs normal haemodynamics, adjusted for comorbid lung and heart disease
- Survival negatively correlated with mPAP and PVR in whole population
Observational data: associations, not effects.
Further findings
- Underlying heart or lung disease in patients with mPAP 21-24 mmHg
- 68.2%
Mildly elevated PVR as predictor of survival among patients with mPAP 21-24 mmHg (adjusted for comorbid lung and heart disease)
- HR (as printed, first)
- 1.33 (95% CI 1.01-1.75, P = .042)
- HR (as printed, second)
- 1.4 (95% CI 1.06-1.86, P = .019)
Symptoms
- Patients with mildly abnormal haemodynamics not more symptomatic than those with normal haemodynamics
Survival excluding heart and lung disease
- Connective tissue disease associated with poorer survival among those with PH
- In mPAP 21-24 mmHg, survival curves diverged only after 5 years
Parts of this Brief are withheld: the automatic checks could not confirm them against the abstract.
Original publication
Predictors of outcomes in mild pulmonary hypertension according to 2022 ESC/ERS Guidelines: the EVIDENCE-PAH UK study. Eur Heart J. Published 24 August 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →